Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients
Abstract
Published data regarding the approach to management of diabetes mellitus in solid organ transplant (SOT) recipients are limited. We performed a retrospective chart review of SOT recipients with diabetes, above 18 years of age, who were usisng dulaglutide. There was a sustained, statistically significant reduction in the primary endpoints of weight, body mass index (BMI) and insulin requirement in 63 SOT recipients at 6, 12 and 24 months, respectively. A total of 59, 50 and 13 recipients were followed during 6, 12 and 24 months, with a mean paired difference for weight reduction of 2.07 ( P value <0.003), 4.007 ( P value <0.001) and 5.23 ( P value <0.034) kgs and a BMI reduction of 0.80 ( P value <0.001), 1.35 ( P value <0.005) and 2.015 ( P value <0.045) kg/m 2 , respectively. The mean paired difference for insulin reduction before and after dulaglutide treatment was 5.94 units ( P value <0.0002). There was no increased risk of malignancy, cardiovascular morbidity, graft‐failure or all‐cause mortality. Gastrointestinal manifestations were rare, even in patients with advanced chronic kidney disease (CKD), and required no change in immunosuppressive agents. Thus, dulaglutide may be considered an important option for diabetes management in SOT.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Data for dulaglutide in solid organ transplant recipients with T2D has shown modest weight loss (-4 kg) and improved glycaemic control.
“Data for dulaglutide in solid organ transplant recipients with T2D has shown modest weight loss (-4 kg) and improved glycaemic control. 522”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [522]
Studies have not found evidence of drug interaction between GLP-1 RAs and immunosuppression, including no changes in dosing or toxicity.
“Studies have not found evidence of drug interaction with immunosuppression, including finding no changes in dosing or toxicity (231-233).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [233]
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works
Basevi, V., Mario, S. D., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,058 · see citing works
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880 · see citing works
Umpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L., & Pechtner, V. (2014) · Diabetes Care · doi:10.2337/dc13-2759 · Cited by 341 · see citing works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Correia, L. C. L., Latado, A., & Porzsolt, F. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1611289 · Cited by 194 · see citing works
Grunberger, G., Chang, A., Soria, G. G., Botros, F. T., Bsharat, R., & Miličević, Z. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03745.x · Cited by 102 · see citing works
Coadministration of Liraglutide With Tacrolimus in Kidney Transplant Recipients: A Case Series
Pinelli, N. R., Patel, A., & Salinitri, F. D. (2013) · Diabetes Care · doi:10.2337/dc13-1066 · Cited by 75 · see citing works
Liou, J.-H., Liu, Y.-M., & Chen, C. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.03.087 · Cited by 55 · see citing works
Garber, A. J. (2010) · PubMed · Cited by 50 · see citing works
Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice
Bisgaard, L. S., Bosteen, M. H., Fink, L. N., Sørensen, C. M., Rosendahl, A., Mogensen, C., Rasmussen, S. E., Rolin, B. C., Nielsen, L. B., & Pedersen, T. X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168396 · Cited by 47 · see citing works
Chen, P., Shi, X., Xu, X., Lin, Y., Shao, Z., Wu, R., & Huang, L. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.09.006 · Cited by 45 · see citing works
Røder, M. E. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317735283 · Cited by 34 · see citing works
Guo, H., Li, H., Wang, B., Ding, W. Q., Ling, L., Yang, M., Gu, Y., & Niu, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000464118 · Cited by 32 · see citing works
Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist.
Smith, L. L., Mosley, J., Parke, C. K., Brown, J., Ls, B., & Phan, L. D. (2016) · PubMed Central · Cited by 29 · see citing works
Sadhu, A., Schwartz, S. S., & Herman, M. E. (2015) · Endocrine Practice · doi:10.4158/ep14569.ra · Cited by 21 · see citing works
Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series
Cariou, B., Bernard, C., & Cantarovich, D. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.10.004 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728 · see citing works
Metabolic complications in liver transplantation recipients: how we can optimize long-term survival
Azhie, A., Sheth, P., Hammad, A., Woo, M., & Bhat, M. (2021) · Liver Transplantation · doi:10.1002/lt.26219 · Cited by 34 · see citing works
Post-transplantation diabetes mellitus in pediatric patients
Grundman, J. B., Wolfsdorf, J. I., & Marks, B. E. (2020) · Hormone Research in Paediatrics · doi:10.1159/000514988 · Cited by 12 · see citing works
- Authors
- Singh, P., Pesavento, T. E., Washburn, K., Walsh, D., & Meng, S.
- Affiliations
- The Ohio State University (US)
- Corresponding author
- Singh, Priyamvada
- Venue
- Diabetes Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-01-20
- Volume
- 21
- Issue
- 4
- Pages
- 1061-1065
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2904047928
- Cited by
- 86
- References
- 16
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 19 · 2023: 12 · 2022: 5 · 2021: 13 · 2020: 9 · 2019: 3
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Keywords
- dulaglutide, diabetes mellitus, solid organ transplant recipients, weight loss, body mass index, insulin requirement, gastrointestinal adverse effects, chronic kidney disease, immunosuppressants, graft failure, mortality
- MeSH terms
- Adult, Aged, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Graft Rejection, Graft Survival, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Immunosuppressive Agents, Insulin, Male, Middle Aged, Recombinant Fusion Proteins, Retrospective Studies, Heart Transplantation, Kidney Transplantation, Liver Transplantation, Organ Transplantation, Incretins, Transplant Recipients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
